Skip to main content

Douglas
A.
Jabs
,
MD

Director, Center for Clinical Trials and Evidence Synthesis
Professor
Douglas Jabs

Departmental Affiliations

Primary
Division
Clinical Trials and Evidence Synthesis
School of Medicine
Joint

Contact Info

Research Interests

Clinical trials; research methodology; uveitis, uveitis treatment; uveitis diagnosis
Experiences & Accomplishments
Education
MD
Johns Hopkins University
1977
MBA
Johns Hopkins University
2000
MS
Johns Hopkins University
1998
AB
Dartmouth University
1973
Overview
Dr. Jabs is an experienced clinician scientist and uveitis expert, with a long track record in clinical trials, cohort studies, and translational research. Dr. Jabs’ work focuses on performing clinical trials in the field of uveitis and developing ‘best practice’ guidelines for the management of the uveitides, particularly with regard to long-term outcomes of these chronic diseases. Dr. Jabs has served as the chair of numerous NIH-funded multicenter, national and international, randomized, comparative effective trials, and of long-term prospective cohort studies. He has authored over 320 peer-reviewed journal articles and over 45 book chapters.
Honors & Awards
2002 Research to Prevent Blindness Senior Scientific Investigator Award 2008 EyeCare America, Lifetime Volunteer Physician Award 2010 American Academy of Ophthalmology 2010 “Best Paper” Award 2010 LXVII Edward Jackson Lecture at the American Academy of Ophthalmology 2015 Johns Hopkins University Society of Scholars 2019 American Academy of Ophthalmology Lifetime Achievement Award
Select Publications
Representative publications
  • Jabs DA, Van Natta ML, Trang G, Jones NG, Milush JM, Cheu R, Klatt NR, Danis RP, Hunt PW. Association of age-related macular degeneration with mortality in patients with AIDS; role of systemic inflammation. Am J Ophthalmol 2019;199:230-7.
  • Multicenter Uveitis Steroid Treatment Trial Research Group. Periocular triamcinolone versus intravitreal triamcinolone versus intravitreal dexamethasone implant for the treatment of uveitic macular edema: The PeriOcular versus INTravitreal corticosteroids for uveitic macular edema (POINT) Trial. Ophthalmology 2019;126:283-95.
  • Jabs DA. Immunosuppression for the uveitides. Ophthalmology 2018;125:193-202.
  • Writing Committee for the Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow-up Study Research Group. Association between long-lasting intravitreous fluocinolone acetonide implant vs systemic anti-inflammatory therapy and visual acuity at 7 years among patients with intermediate, posterior, or panuveitis. JAMA 2017;317:1993-2005.
  • Jabs DA, Busingye J. Approach to the diagnosis of the uveitides. Am J Ophthalmol 2013:156:228-36.
Projects
Macular Edema Trials Associated with MUST
Immunologic determinants of age-related macular degeneration
Developing Classification Criteria for the Uveitides
ADalimumab Vs conventional ImmunoSupprEssion (ADVISE) for uveitis Trial